Telomerase Vaccine Plus Checkpoint Blockade Targets HPV-Driven Cancers
A completed Phase 2 trial tests UCPVax cancer vaccine combined with atezolizumab in cervical, anal, and head-and-neck cancers.
20 articles
A completed Phase 2 trial tests UCPVax cancer vaccine combined with atezolizumab in cervical, anal, and head-and-neck cancers.
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
A French trial investigated whether circulating immune cell profiles, specifically CD226 expression, could predict who responds to Atezolizumab/Bevacizumab in advanced HCC.
Engineered immune cells target liver cancer protein in phase I safety study, though trial ended early with 10 patients.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
New viral therapy ASP9801 targets solid tumors directly, potentially offering hope for patients with advanced metastatic cancer.
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.
French researchers studied how tiny cellular packages called exosomes may help melanoma cells resist treatment and spread throughout the body.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Autologous NK cell therapy combined with immunotherapy tested in 27 patients with treatment-resistant cancers.
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.